Lenvatinib plus pembrolizumab delays the time to deterioration of quality of life
Gynaecologic malignancies

Lenvatinib plus pembrolizumab delays the time to deterioration of quality of life

In advanced pre-treated endometrial cancer, patient-reported outcomes support efficacy benefits of the combination therapy 

Read more

Don't miss

  • Poster Display session
    17 June 2022, 12:15-13:00
  • Keynote lecture
    17 June 2022, 14:15-14:45
  • Mini Oral session
    18 June 2022, 13:00-14:00

EDITORIAL

HIGHLIGHTS

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.